Introduction We aimed to describe changes in survival in alcoholic hepatitis (AH) over time by examining published data. Method A systematic literature search of Ovid Embase and PubMed was undertaken using the MESH terms 'hepatitis, alcoholic' to identify randomised controlled trials (RCT) and observational studies (OS) in alcoholic hepatitis. Data were extracted from included studies regarding 28 day, 90 day, 180 day mortality, as well as biochemical and clinical data. Results After review of the literature search results, 79 studies published between 1971 and 2016 were analysed, which included data from a total of 8318 patients. Overall mortality from AH was 25% at 28 days, 29% at 90 days and 38% at 180 days after admission. No changes in mortality over time were observed in univariable analysis at 28 days or 90 days after admission (Pearson correlation r À0.207, p=0.107, and r 0.109 p=0.553 respectively) ( figure 1A and 1B) . A statistically significant increase in mortality was seen in 180 day mortality (r 0.446 p=0.048) ( figure 1C ). However, after meta-regression to adjust for other factors associated with mortality at each time point, no changes in mortality were seen. Sub-group analysis of RCT and OS did not reveal any differences between type of study. Conclusion There has not been a significant improvement shortmedium mortality from AH over the last four decades, despite much research and general medical innovation. This is not explained by changes in severity of disease. This emphasises the urgent need for effective treatments for this alcoholic hepatitis.
Introduction We aimed to describe changes in survival in alcoholic hepatitis (AH) over time by examining published data. Method A systematic literature search of Ovid Embase and PubMed was undertaken using the MESH terms 'hepatitis, alcoholic' to identify randomised controlled trials (RCT) and observational studies (OS) in alcoholic hepatitis. Data were extracted from included studies regarding 28 day, 90 day, 180 day mortality, as well as biochemical and clinical data. Results After review of the literature search results, 79 studies published between 1971 and 2016 were analysed, which included data from a total of 8318 patients. Overall mortality from AH was 25% at 28 days, 29% at 90 days and 38% at 180 days after admission. No changes in mortality over time were observed in univariable analysis at 28 days or 90 days after admission (Pearson correlation r À0.207, p=0.107, and r 0.109 p=0.553 respectively) (figure 1A and 1B). A statistically significant increase in mortality was seen in 180 day mortality (r 0.446 p=0.048) ( figure 1C ). However, after meta-regression to adjust for other factors associated with mortality at each time point, no changes in mortality were seen. Sub-group analysis of RCT and OS did not reveal any differences between type of study. Conclusion There has not been a significant improvement shortmedium mortality from AH over the last four decades, despite much research and general medical innovation. This is not explained by changes in severity of disease. This emphasises the urgent need for effective treatments for this alcoholic hepatitis. Introduction Liver biopsy is the gold standard method for diagnosing and staging NAFLD, up to date,the steatosis grade and fibrosis stage are reported using semi-quantitative scores with hisg Inter-observer variability.We aimed to develop an automated method for steatosis and fibrosis quantitation using routine histological images of NAFLD patients. Method 118 consecutive patients with biopsy-confirmed NAFLD were retrospectively evaluated. Biopsies were stained with H and E and Sirius red, and then scored by two histopathologists. Each image was then analysed by the automated software in two stages: Machine learning clustering and MorphologicalImage Processing ( Figure 1 ). Fat% and fibrosis% computed by the software were compared with the manual annotationfor all cases. Results TThere was good correlation between fat% and steatosis grade but with significant overlap between groups: Anova 50.9, p<0.001 ( Figure 2a Introduction Non-invasive characterisation of hepatic steatosis and fibrosis based on Fibroscan elastographyand controlled attenuation paratmeter (CAP) is used widely for diagnosis and follow up in NAFLD. The aim of this study was to assess the correlation between the degree of steatosis as determined by CAP and the degree of fibrosis by liver stiffness measurements unisg the fat and collagen quantitation as gold standard. Method 80 consecutive patients with biopsy confirmed NAFLD and transient elastography with CAP score.Biopsies were digitalized at 2x magnification and then analysed by our automated software.Fat and fibrosis quantitation wereexpressed as percentages of the relative areas of fat and collagen respectively and of tissue.
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Results Correlation between CAP score and fat% was statistically significant (p=0.002, Rho=0.45). Regression analysis revealed an R2=0.206 ( figure 1a) . The AUROC foridentifying fat >5% was 0.82(p=0.001, 95%CI=0.71-0.92) with the best cutoff at 250 dB/m (95% sens, 60% specificity).Correlation between liver stiffness and fibrosis quantitation (%) was statistically significant (p<0.001, Rho=0.802) with anR2 of 0.679 (figure 1b).When our cohort was split to those with fat%£10% and>10% in the liver biopsies there was no difference between liverstiffness and fibrosis quantitation in Pearson's correlation: Rho=0.883 and Rho=0.843 respectively (figure 2).
Abstract PWE-094 Figure 1 Conclusion Liver stiffness is a reliable noninvasive tool for estimating the severity of fibrosis in NAFLD. The presenceof severe steatosis evaluated by fat quantitation in liver biopsies did not influence liver stiffness measurements. Introduction Chronic intestinal failure is defined by the lack of absorption of micronutrients, macronutrients or water requiring intravenous support. The absorptive capacity of the gut is determined by length of gut present in continuity, enteric adaptation and speed of transit. Frequently patients require intravenous micronutrient support. Following intestinal transplant (ITx) the graft is able to absorb both micro and macronutrients such that parenteral nutrition (PN) is no longer required. We studied transplanted patients in a single centre to assess the absorption of micronutrients. Method This was a retrospective analysis of a prospective database. Results were taken from patients being assessed for ITx, then at 3 monthly intervals, and then yearly. Data are inclusive of results either side of the specified timepoint. Data were analysed on Prism using one-way ANOVA and Tukey multiple comparisons test. Data reported as mean ±95% confidence interval. Results 34 patients received 35 transplants. Mean age was 41.9y (range 23-73). M/F: 22:14. Median follow up was 774d (range 16-3029). Indications included Crohn's disease (7/36,19%), intra-abdominal desmoids (4/36,11%), visceral neuromyopathy (5/36,14%), vascular ischaemia (6/36,17%), radiation enteritis (2/36,6%), NET (1/34,3%), pseudomyxoma peritonii (6/36,17%) and other (5/36,13%). Zinc, folic acid, B12, Vitamin A and Vitamin D were significantly different using one way ANOVA: Zinc (p<0.0001) with significant Tukey for pre-ITx (16.9±1.07) vs. 12m (14.2±1.2,p<0.05), vs. 24m (13.5±1.5,p<0.05), vs. 36m (12.9±1.4,p<0.005) and vs. 48m (13.2±1.2,p<0.005); Folic acid (p=0.0006) with significant Tukey for pre-ITx (10.1±0.9) vs. 3m (6.6±1.0,p<0.05), vs. 6m (5.71±1.3,p<0.05); and between 3m vs. 24m (11.7±2.5,p<0.005) and 6m vs. 24m (p<0.005); B12 (p=0.0349) with significant Tukey for 6m (883.2±202.8) vs. 24m (555.8±121.3); Vitamin A (p<0.0001) with significant Tukey for pre-Tx (1.87±0.41) vs 3m (3.27 ±0.56,p<0.001), 3m vs. 24m (1.79±0.32,p<0.001) and vs. 48m (2.22±0.34,p<0.05), 6m (2.80±0.55) vs. 24m (p<0.05); Vitamin D (p=0.0469) without significant Tukey for any timepoints. Conclusion Observing micronutrient changes aids our understanding of transplanted graft function and nutritional intake. The reduction in zinc, folate and B12 is perhaps more physiological than clinically significant, as the levels were within the normal range and may reflect over-treatment when on PN, though it is interesting to observe folate rising back to a higher level after 6m. It is reassuring to observe that the ITx is not deleterious to micronutrient metabolism. Introduction Iron is an essential nutrient. However, in animal models, excess unabsorbed dietary iron which can reside within the colon for hours to days, has been shown to exacerbate inflammatory bowel disease and intestinal cancer. However, to date it remains unclear whether these detrimental effects are mediated though epigenetic modifications. Thus, the aim of this study was to chronically expose colonocytes to iron and determine the impact on genome-wide methylation. Method Caco-2 cells were co-cultured in the presence or absence of iron (10 mM), with or without a dietary iron chelator (Manucol LD, 0.1% (w/v)) for 30 days. After this time period, DNA was harvested and methylation signatures were examined using Illumina Infinium Methylation450K BeadChip analysing 4 85 512 methylation sites. Intensity IDAT files were processed using ChAMP, which was used for the pre-processing and normalisation with SWAN. Probes found with an adjusted p-value of >0.01 were classified as significant differentially methylated probes (DMPs). Protein expression changes were examined by Western blotting. Results The most significant methylation changes were observed between iron treated cells and control untreated cells (total of 60.04% DMPs with p adj >0.01); all DMPs were found to by hypomethylated. Pathway specific genes that were hypomethylated included PI3K/AKT (18 genes), MAPK (16 genes), and RAP1/RAS (28 genes). Within the MAPK pathway, epidermal growth factor receptor (EGFR) was found to be 23.5% hypomethylated in the iron treated group compared to control cells (b=10.27); this increase was translated in the protein expression of EGFR. Relatively fewer changes were observed between iron and iron with Manucol LD treatment groups (total of 6.65% DMPs with P adj >0.01). No changes in methylation were observed between alginate treatments compared to control nontreated cells (0% DMPs with P adj >0.01).
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Abstract PWE-096 Figure 1 Conclusion These studies suggest that chronic exposure of colonocytes to iron results in marked hypomethylation and this may be a contributory factor in iron mediated intestinal disease. Manucol LD had no impact on DNA methylation throughout the treatment. The contribution of the methylation changes to cell phenotype is currently being examined. Disclosure of Interest None Declared
